Teva Pharmaceutical's Stock Tumbles on Outlook - WSJ
Drug maker Teva's U.S. unit indicted on price-fixing charges - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Teva Tries to Put an End to the Opioid Wars - WSJ
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame. | Barron's
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Announces Abstracts at the ACAAI Annual Scientific Meeting
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva Pharmaceuticals reports earnings on Wednesday. Here's what to expect - MarketWatch
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Teva shares drop 3% after rival generic product approved and launched - MarketWatch
Teva Pharmaceutical Stock Could Double | Barron's
Prosecutors Sue Teva's U.S. Business Over Charitable Donations - WSJ
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva - Updates, News, Events, Signals & Triggers
Drug Stock Due for Another Climb on the Charts
Teva Pharmaeutical Stock Gets Upgrade From Analyst | Barron's
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Pharmaceutical TEVA Investment Analysis - MarketWatch
Teva's Battered Stock Looks Extremely Cheap | Barron's
TEVA -- Is Its Stock Price A Worthy Investment? Learn More.
Teva shares surge on corporate shake-up - MarketWatch
Teva Stock Is Falling as an Analyst Says It Needs 'Numerous Litigation Wins' | Barron's
